Introduction
Today passive cancer immunotherapy with therapeutic monoclonal antibodies (mAbs) that have the ability to directly mediate anti-tumor responses belongs to the standard portfolio in cancer treatment [1] . The LeY carbohydrate antigen (CD174) is expressed on the majority of human cancers of epithelial origin whereas expression on normal tissue is limited to epithelial cells of the esophagus, stomach, the proximal small intestine, some acinar cells of the pancreas and resting granulocytes [1] [2] [3] [4] [5] . Regarding tumor cells, predominantly adenocarcinomas of the lung, breast, colorectal, gastric, pancreatic, prostate and ovarian cancers have been tested positive for LeY [2, [6] [7] [8] [9] . Pronounced expression of LeY in different tumors is associated with decreased survival and higher metastatic potential [10] [11] [12] [13] [14] . In the past, a variety of murine mAbs have been generated against LeY, their antitumor activities have been explored and have demonstrated anti-tumor activity in tumor cell models in vitro, animal models and clinical studies [1, 2, 6, [15] [16] [17] [18] [19] [20] [21] [22] .
Based on the promising effects found with murine mAbs, humanized LeY specific mAbs have been designed which have shown improved pharmacokinetics in vivo and in humans [23] [24] [25] .
A Phase I bio-distribution and pharmacokinetic trial with the humanized IgG3/κ mAb 3S193 in pts with LeY positive, advanced epithelial cancer have demonstrated selective targeting of tumors with no evidence of any consistent normal tissue uptake [26, 27] . For another humanized anti-LeY mAb, IGN311 (now renamed to MB311), a Phase I dose escalation study was recently conducted and safety, tolerability, pharmacokinetic data, anti-tumor activity and immunologic parameters were assessed [28, 29] . Intravenous application of MB311 in this study enabled the patients' serum to lyse tumor cells by two mechanisms, Complement Dependent Cytotoxicity (CDC) and Antibody Dependent Cellular Cytotoxicity (ADCC). Moreover, disseminated tumor cells detectable in two patients before treatment were eliminated after treatment with MB311 [28] . In animal models, MB311 was also shown to block signal transduction through LeY glycosylated growth factor receptors such as EGFR and Her2-neu on tumor cells [24, 30] .
In the present study MB311 was tested for the first time in pts with malignant effusion (ascites or pleura) with the primary objective to examine safety and tolerability as well as pharmacokinetics. Secondary objectives were assessment of pharmacodynamics, immunological parameters, and-as a clinically relevant parameter regarding efficacy-the volume of the malignant effusion. MB311 was well tolerated, permeated into malignant effusion and attracted immune cells leading to decreased tumor cell counts in the effusion. About 20 years ago, disseminated tumor cells were regarded as important marker [31] and have gained recently increasing attention and relevance as a diagnostic and prognostic factor in cancer therapy [32] [33] [34] [35] [36] . Notably, in the pt with the strongest LeY expression as well as concomitant Her2/ neu expression on the malignant cells in the effusion a dramatic effect on LeY, EpCAM (CD326) and Her2/neu positive tumor cells and a clinically significant reduction of the effusion volume were found following application of MB311.
Patients and Methods

Study Synopsis
The primary objective of the study was to assess safety, tolerability and pharmacokinetics of two doses of MB311 administered by intravenous bolus infusion to pts with malignant effusion (ascites or pleural effusion). Secondary objectives were assessment of the response based on the malignant effusion volume by volumetric measurement at baseline and after therapy (via computer tomography). X-ray or ultrasound examination of effusion was to be performed after 4 weeks-only in case of response an additional CT scan was to be performed. Also the number of LeY expressing cells in pleural effusion/ ascites was determined. Additionally, the functional activity of MB311 in the pleural effusion/ascites by CDC and ADCC reactivity; the amount of disseminated tumor cells in peripheral blood and the tumor response (other than tumor effusion; e.g. stage and size of the primary tumor) were measured.
Study Design and Treatment
Open-label, multiple dose, uncontrolled study enrolling 5 pts evaluable for safety and tolerability assessment. The study was performed at the department of oncology of the Medical University Clinic Graz, 8036 Graz, Austria. All subjects received two administrations of 100 mg MB311. The mAb was administered intravenously by prolonged infusion for two hours on day 1 and 7. Pts were followed up for a period of 4 weeks. Volumetric measurements of effusion at baseline and at the end of study at week four were performed. Effusion-related symptoms and adverse events were assessed weekly. Pts with significant progression of effusion causing symptomatic deterioration would have been removed from the trial and treated at the discretion of the investigator. Also if concomitant systemic anti-tumor therapy was required the pt would have been removed from the evaluation. All pts who received study medication were included in the safety/olerability analysis. The study was conducted in accordance with the latest revision of the Declaration of Helsinki, the requirements of Good Clinical Practice of the European Community (CPMP/ICH/135/95) and European Clinical Trials Directive 2001/20/EC. Written, voluntary informed consent to participate in this study was obtained prior to enrolment into the study and for performing of any study specific evaluations. 
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Pharmacokinetic (PK)
Sera obtained at different time points after infusion of MB311 were incubated in 96-well plates coated with MMA383 (anti-idiotypic antibody to MB311 mimicking the LeY antigen) in appropriate dilutions. After washing, a mouse anti-human IgG1 HRP conjugate was added. After washing, color was developed using OPD as substrate, stopped with H 2 SO 4 and read at 492/620 nm. A standard curve of MB311 spiked into normal human serum was used for calibration.
Human Anti-Human Antibody (HAHA) Response
HAHA reactivity was assessed using a surface plasmon resonance based assay as described previously [37] . This highly sensitive assay monitors binding to immobilized MB311 and to an isotype matched control antibody. A positive HAHA response was defined as at least two-fold increase in response units (RUs) compared to the matched control antibody and absolute value >50 RUs.
Complement Dependent Cytotoxicity (CDC)
SKBR3 (LeY positive adenocarcinoma breast cancer cell line) cells were incubated with 51 Cr, washed and incubated for 60 minutes at 37˚C with serial dilutions of patient sera, thereby using patient's complement. Supernatants were collected and counted for released 51 Cr ("Cs") using a Packard γ-counter. Values for spontaneous release ("Sr") and maximum release ("Mr") were measured after incubation of representative samples with medium alone and with detergent (20% SDS) respectively. Cytotoxicity was calculated as percentage of cell lysis by the formula 100 × (Cs-Sr)/(Mr-Sr). The percentage cytotoxicity was plotted against the logarithm of the antibody concentration (ng/ml).
Antibody Dependent Cellular Cytotoxicity (ADCC)
SKBR3 cells were incubated for 2 hours with 51 Cr, washed and plated into 96-well microplates. Effector cells (peripheral blood mononuclear cells from healthy volunteers) were freshly prepared and added to the target cells at a E:T ratio of 40:1. Heat inactivated serum samples were diluted 1:20 and incubated at 37˚C for 16 hours in a CO 2 -incubator, cell supernatants were collected and counted for released 51 Cr ("Cs") using a Packard γ-counter. Values for spontaneous release ("Sr") and maximum release ("Mr") were measured after incubation of representative samples with medium alone and with detergent (SDS) respectively. Cytotoxicity was calculated as percentage of cell lysis by the formula 100 × (Cs-Sr)/ (Mr-Sr). The percentage cytotoxicity was plotted against the logarithm of the antibody concentration (ng/ml).
Microscopic and Immuno-Histological Analysis
Effusion specimens were embedded in agarose gel and subsequently formalin fixed and paraffin embedded following standard procedures. Serial 4 μm sections were cut, and incubated with anti-EpCAM (Epithelial Cell Adhesion Molecule), LeY, calretinin, CD45, HER2/neu and mouse-anti-human IgG mAbs followed by detection using a streptavidin biotin method on an autostainer (DAKO, Denmark).
Analysis of Effusion Sample Using Flow Cytometry
Cells obtained by drainage of ascites or pleurocentesis were washed, treated for 30 minutes on ice with blocking buffer (PBS + 10% FCS), and incubated on ice for 30 minutes with PE-or FITC labeled antibodies directed against LeY, EpCAM or CD45. Samples were counted after an incubation with 7-AAD (20 minutes) using a BD FACSCalibur®. Results were measured in percentage of gated cells on the basis of all viable cells after correction for unstained control and isotype control.
Results
All included pts (n = 5) had a histologically proven LeY All pts received prior treatment for metastatic disease either with chemotherapy for median 2 lines (range 1 -4) and/or with anti-hormonal therapy (median 3 lines) in 2/3 pts with receptor-positive breast cancer. In addition, pt 4 had a history of treatment with trastuzumab for metastatic disease due to HER2/neu2 positive breast cancer ( Table 2) .
Safety and Tolerability (n = 5)
MB311 was well tolerated with mild to moderate nausea and vomiting in 2 pts which could be successfully managed with 5HT3 blocker and metoclopramid. Furthermore, one episode of skin rash was observed in pt 2 after the first cycle which could be resolved and subsequently prevented with the administration of H1 and H2 blockers.
Pharmacokinetics & Pharmacodynamics (n = 4)
Systemic antibody levels in serum were about 30 µg/ml after the first and about 55 µg/ml after the second administration of 100 mg of MB311 (Figure 1 , blue symbols). Volume of distribution corresponded therefore to the whole average plasma volume, after an apparent saturation of internalization and recycling mechanisms following the first administration. ADCC and-to a lesser extent-CDC reactivity against LeY positive tumor cells was induced in all pts (Figure 1 , red and green symbols, respectively). Penetration of MB311 into the effusion sample was quantified by anti-idiotypic ELISA and was found in all four evaluable pts (Figure 2(a) ). Moreover, binding of MB311 mAb to tumor cells could be detected in 2/4 pts in the effusion sample (Figure 2(b) ). Furthermore, a significant increase in ADCC in the effusion sample was found in 4/4 pts (Figure 3) . A mild to moderate HAHA response was detected in all patients (data not shown), similarly as described previously [29] .
Clinical Efficacy (n = 5)
Reduction of effusion volume was observed in 1/5 pts (pt 4) and a stabilisation of effusion volume and/or tumor marker in two out of five pts (pts 2, 5) ( Table 3) . A de- Abbreviations: CEA = Carcino-Embryonic Antigen, n.a. = not analysed.
crease in the number of circulating tumor cells (determined by LeY and/or EpCAM staining) was shown in three out of five patients (pts 2, 4, 5) by immunohistochemistry and/or flow cytometry (Tables 1 and 2, Figures 4(c) and (d) ). In addition, a significant infiltration of CD45 positive lymphocytes was noted by immunohistochemistry (IHC) in four out of five pts (pts 1, 3, 4, 5) in the effusion sample, which in two patients (pts 4, 5) correlated with a reduction of tumor cells in the same samples (Tables 1 and 2, Figures 4(e) and (f) ). Flow cytometry results of available effusion samples confirmed an increased infiltration of CD45 positive cells for pts 1, 3 and 4 ( Table 1) . Most interestingly, in pt 4-with strong Her2/neu positive tumor cells in the effusion before treatment-a dramatic decrease of Her2/neu positive tumor cells following MB311 treatment was found (Figures 4(g) and (h) ).
Discussion
Targeted cancer immunotherapy remains in the focus of cancer treatment [38] with the passive approaches belonging to the standard clinical treatment scheme. So far primarily monoclonal antibody therapies targeting protein based tumor associated antigens achieved approval, but passive immunotherapies targeting tumor associated carbohydrate antigens may turn out of being attractive development candidates. The anti-LeY mAb MB311 shows a favourable safety profile with manageable and reversible side effects like nausea, vomiting and skin rash. It has been published that LeY can be expressed as glyco-determinant on Her2/neu and related growth factor receptors on tumor cells (40) . In the present study the number of Her2/neu positive tumor cells in the effusion was dramatically reduced following treatment with MB311 correlating also with a significant reduction in effusion volume.
Measuring the puncture-free survival time is an accepted and relevant parameter of assessing the clinical treatment efficacy in patients suffering from malignant ascites [39] . Also, the clinical response (disappearance of ascites accumulation) mediated by catumaxomab was found to correlate with the elimination of tumor cells [40] . Catumaxomab is a bispecfic (EpCAM/CD3) mAb that is approved in Europe for the intraperitoneal treatment of patients with ascites originating from epithelial tumors. Regarding MB311 (which was applied intravenously) the reduction of the effusion volume which were strongly positive for LeY at week 1 is in accordance with our previous data showing the eradication of disseminated tumor cells in the blood of two pts with high LeY expression of their primary tumor [28] . Regarding the anti-tumor activity of MB311 effector mechanisms, CDC and ADCC have been demonstrated against LeY positive tumor cells in ex vivo studies [28] . Furthermore, MB311 has been also shown to block signal transduction through LeY glycosylated growth factor receptors such as EGFR and Her2-neu on tumor cells as demonstrated in cell culture and in in vivo studies [24, 30] . The combination of immunological effector mechanisms of MB311 together with the cytotoxic and cytostatic effects on EGFR and Her2-neu expressing tumor cells may underline the antitumor effect of MB311 in pts with LeY expressing tumor cells in effusion.
Conclusions
The presented study demonstrates that MB311 has the potency to eradicate LeY positive tumor cells in ascites which was also translated into a reduction of the ascites volume. Besides the potential of MB311 to eradicate disseminating tumor cells of a certain LeY expression status it might also lie in the combination with already established therapeutic mAbs like Trastuzumab. The present study was an exploratory study with a very specific setting providing an early idea about immediate in vivo effects against malign tumor cells in patients. As a [41] that LeY also plays an essential role in ovarian cancer. Additionally, further studies may help select favourable tumor entities by examinations on differences in cell promoting effect if LeY is expressed as part of Her2/neu in contrast to expression of LeY on other backbone structures or expressed as soluble LeY [42] . With regard to Trastuzumab it has been shown that-in vivo-ADCC is one of the main anti-tumor mechanisms besides CDC and anti-proliferative effects [43] . The effusion ex-vivo results with MB311 suggest a more prominent role for ADCC when compared to the CDC activity, which would also point towards a pivotal role of ADCC in MB311 mediated cytotoxicity to facilitate induction of immune effectors suppressed by the tumor microenvironment. To confirm this observation, additional studies are required. Interestingly, an ADCC improved (de-fucosylated) version of MB311, designated MB314, has shown increased ADCC reactivity in vitro [44] and also an interesting cytokine release profile that might further increase its efficacy [45] .
